tradingkey.logo

Sarepta Therapeutics Inc

SRPT
View Detailed Chart

15.960USD

-0.460-2.80%
Market hours ETQuotes delayed by 15 min
1.57BMarket Cap
LossP/E TTM

Sarepta Therapeutics Inc

15.960

-0.460-2.80%
Intraday
1m
30m
1h
D
W
M
D

Today

-2.80%

5 Days

+23.91%

1 Month

-6.67%

6 Months

-85.97%

Year to Date

-86.87%

1 Year

-88.78%

View Detailed Chart

Agency Rating

Analyst Rating

Based on 30 analysts
HOLD
Current Rating
31.153
Target Price
85.99%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell

Peer Comparison

172
Total
5
Median
8
Average
Company name
Ratings
Analysts
Sarepta Therapeutics Inc
SRPT
30
Biogen Inc
BIIB
37
Vertex Pharmaceuticals Inc
VRTX
34
Alnylam Pharmaceuticals Inc
ALNY
33
Amgen Inc
AMGN
33
Gilead Sciences Inc
GILD
30
1
2
3
...
35

Indicators

The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

1m
15m
30m
1h
D
W
M
1m
15m
30m
D
Neutral
Sell(5)
Neutral(4)
Buy(3)
Indicators
Sell(1)
Neutral(4)
Buy(1)
Indicators
Value
Direction
MACD(12,26,9)
1.540
Neutral
RSI(14)
43.507
Neutral
STOCH(KDJ)(9,3,3)
60.048
Buy
ATR(14)
2.819
High Vlolatility
CCI(14)
22.537
Neutral
Williams %R
51.748
Neutral
TRIX(12,20)
-2.112
Sell
StochRSI(14)
95.124
Overbought
Moving Average
Sell(4)
Neutral(0)
Buy(2)
Indicators
Value
Direction
MA5
14.958
Buy
MA10
14.200
Buy
MA20
16.549
Sell
MA50
25.079
Sell
MA100
43.390
Sell
MA200
81.048
Sell

Financial Indicators

EPS

No Data

Total revenue

No Data

Company

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on helping patients through the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. It has developed multiple approved products for the treatment of Duchenne muscular dystrophy (Duchenne) and is developing potential therapeutic candidates for a range of diseases and disorders, including Duchenne, Limb-girdle muscular dystrophies (LGMDs) and other neuromuscular and central nervous system (CNS) related disorders. The Company has developed and commercialized four approved products for the treatment of Duchenne: EXONDYS 51 (eteplirsen), Injection (EXONDYS 51), VYONDYS 53 (golodirsen) Injection (VYONDYS 53), AMONDYS 45 (casimersen) Injection (AMONDYS 45), and ELEVIDYS. Its pipeline includes over 40 programs at various stages of discovery, pre-clinical and clinical development.
Ticker SymbolSRPT
CompanySarepta Therapeutics Inc
CEOMr. Douglas S. (Doug) Ingram, Esq., J.D.
Websitehttps://www.sarepta.com/
KeyAI